A prospective multicenter study (>600 patients) is currently ongoing to confirm the promising potential of the CD8+ TEMRA/CD4+ TReg ratio as a potential biomarker for predicting the healing outcome in human bone fracture patients. The gene discussed is CD8A; the disease is bone fracture.